Home Mf Research Whiteoak Capital Pharma And Healthcare Fund Regular Plan Growth
WhiteOak Capital Mutual Fund

Mutual Fund Research

Whiteoak Capital - Pharma And Healthcare Fund - Regular Plan - Growth

Fund Performance

-
-
Historical NAV
  • 1W
  • 2W
  • 1M
  • 3M
  • 6M
  • 1Y
  • SI

SIP Returns

Historical performance of a ₹1,000 monthly SIP

Historical data
Investment Period SIP Start Date Amount Invested Current Value Absolute Return
One Week 2026-10-27 ₹1,000.00 ₹1,029.46 +2.95%
Two Week 2026-10-19 ₹1,000.00 ₹1,062.53 +6.25%
One Month 2026-10-05 ₹1,000.00 ₹1,024.91 +2.49%
Three Months 2026-08-05 ₹3,000.00 ₹3,024.41 +0.81%
Six Months 2026-05-07 ₹6,000.00 ₹6,290.77 +4.85%
One Year 2025-11-03 ₹12,000.00 ₹13,647.27 +13.73%
Since Inception 2024-01-16 ₹35,000.00 ₹45,316.31 +29.48%

Past returns are historical, not guaranteed. SIP values depend on the dates and NAVs used.

Return Calculator

Explore SIP and one-time investment scenarios

₹1,000₹50,000
Investment Duration

Projection uses the selected fund return as an annualized assumption. It does not predict future performance.

Estimated Investment Summary

Investment
₹0
Maturity Value
₹0
Abs. Returns
₹0
Assumed Annual Return
0%

Illustrative values only. Market returns are not fixed or guaranteed.

Portfolio Allocation

Explore asset allocation, sector exposure and company holdings.

Equity
N/A
Debt
N/A
Others
N/A

Sector Allocation

Distribution across different sectors

Pharmaceuticals & Biotechnology 61.16%
Healthcare Services 23.00%
Other 6.13%
Chemicals & Petrochemicals 3.34%
Sovereign 3.15%
Consumer Durables 1.84%
Healthcare Equipment & Supplies 1.38%

Top Holdings

Company-wise portfolio exposure

Divi's Laboratories Limited 8.36%
Sun Pharmaceutical Industries Limited 7.11%
Torrent Pharmaceuticals Limited 6.26%
Laurus Labs Limited 3.91%
Apollo Hospitals Enterprise Limited 3.75%
Cipla Limited 3.68%
Sai Life Sciences Limited 3.28%
IPCA Laboratories Limited 2.88%
Zydus Lifesciences Limited 2.81%
Neuland Laboratories Limited 2.60%
Dr. Lal Path Labs Limited 2.35%
Corona Remedies Limited 2.34%
Thyrocare Technologies Limited 2.27%
Aurobindo Pharma Limited 2.09%
Ajanta Pharma Limited 2.01%
Krishna Institute Of Medical Sciences Limited 1.85%
Max Healthcare Institute Limited 1.84%
Shaily Engineering Plastics Limited 1.84%
Global Health Limited 1.82%
Narayana Hrudayalaya Limited 1.61%
Anthem Biosciences Limited 1.57%
Vijaya Diagnostic Centre Limited 1.56%
Onesource Specialty Pharma Limited 1.55%
Acutaas Chemicals Limited 1.45%
Navin Fluorine International Limited 1.41%
Fortis Healthcare Limited 1.36%
Aarti Pharmalabs Limited 1.20%
Mankind Pharma Limited 1.20%
Procter & Gamble Health Limited 1.18%
Molbio Diagnostics Limited 1.15%
Rainbow Childrens Medicare Limited 1.15%
Piramal Pharma Limited 1.06%
Aether Industries Limited 1.05%
Kovai Medical Center and Hospital Limited 0.95%
Gland Pharma Limited 0.93%
Senores Pharmaceuticals Limited 0.80%
Jupiter Life Line Hospitals Limited 0.73%
Supriya Lifescience Limited 0.69%
Vimta Labs Limited 0.67%
Innova Captab Limited 0.63%
Nephrocare Health Services Ltd 0.57%
Manipal Health Enterprises Ltd 0.52%
Sudeep Pharma Limited 0.46%
Biocon Limited 0.42%
Tatva Chintan Pharma Chem Limited 0.42%
Orchid Pharma Limited 0.41%
Zota Health Care Limited 0.40%
Novartis India Limited 0.24%
Laxmi Dental Limited 0.23%
Bharat Parenterals Limited 0.10%
91 Days Tbill (MD 05/11/2026) 0.60%
91 Days Tbill (MD 03/12/2026) 0.60%
91 Days Tbill (MD 10/12/2026) 0.53%
182 Days Tbill (MD 05/11/2026) 0.47%
91 Days Tbill (MD 29/10/2026) 0.37%
91 Days Tbill (MD 19/11/2026) 0.32%
91 Days Tbill (MD 22/10/2026) 0.17%
182 Days Tbill (MD 12/11/2026) 0.08%
364 Days Tbill (MD 12/11/2026) 0.01%
Clearing Corporation of India Ltd 5.55%
Net Receivables / (Payables) 0.58%

Risk Ratios & Analysis

Understand the fund’s volatility, benchmark exposure and redemption characteristics.

σ
Standard Deviation
N/A
Return volatility
β
Beta
N/A
Benchmark sensitivity
S
Sharpe Ratio
N/A
Risk-adjusted return
↗
Lock-in Period
N/A
Redemption restriction
◷
Residual Maturity
N/A
Time to maturity
Risk ratio figures are currently unavailable for this scheme. Explanations below are for reference.

Scheme Riskometer

Published risk classification for this scheme

Principal risk level

Investors understand that their principal will be at

Very High Risk

Low
Low to Moderate
Moderate
Moderately High
High
Very High

Riskometer is a scheme risk classification, not a prediction of future performance.

Fund Family

Compare schemes from WhiteOak Capital Mutual Fund by performance, fundamentals and risk.

Returns are historical and do not guarantee future performance.

View All WhiteOak Capital Mutual Fund Funds

Scheme Objective

The investment mandate and purpose of this scheme

To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.

Scheme Details

Investment requirements and key fund information

Fund Information

Min. SIP Amount
N/A
Min. Lumpsum Amount
N/A
AUM (in Cr.)
N/A
Expense Ratio (Regular)
2.76%
Expense Ratio (Direct)
1.09%
Lock-in Period
N/A
Fund Age
N/A
Benchmark
BSE Healthcare TRI

Exit Load

Charges that may apply when you redeem units

N/A

FAQs

Is a Mutual Fund with a Lower NAV Better?

What Are the Charges in Mutual Fund Investments?

What Are the Tax Benefits of Mutual Funds?

Is It a Good Time to Invest in Mutual Funds?

What Is the Difference Between Dividend and Growth Plans?

Should I Invest in Infrastructure Funds?

What Are Sector-Specific Funds/Schemes?

What Happens If I Miss an SIP Payment?

How Can I Compare Different Mutual Funds?